Correlation Between Caribou Biosciences and Cognition Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Caribou Biosciences and Cognition Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Caribou Biosciences and Cognition Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Caribou Biosciences and Cognition Therapeutics, you can compare the effects of market volatilities on Caribou Biosciences and Cognition Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Caribou Biosciences with a short position of Cognition Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Caribou Biosciences and Cognition Therapeutics.

Diversification Opportunities for Caribou Biosciences and Cognition Therapeutics

0.05
  Correlation Coefficient

Significant diversification

The 3 months correlation between Caribou and Cognition is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Caribou Biosciences and Cognition Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cognition Therapeutics and Caribou Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Caribou Biosciences are associated (or correlated) with Cognition Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cognition Therapeutics has no effect on the direction of Caribou Biosciences i.e., Caribou Biosciences and Cognition Therapeutics go up and down completely randomly.

Pair Corralation between Caribou Biosciences and Cognition Therapeutics

Given the investment horizon of 90 days Caribou Biosciences is expected to under-perform the Cognition Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Caribou Biosciences is 1.15 times less risky than Cognition Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Cognition Therapeutics is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  205.00  in Cognition Therapeutics on September 23, 2024 and sell it today you would lose (142.00) from holding Cognition Therapeutics or give up 69.27% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Caribou Biosciences  vs.  Cognition Therapeutics

 Performance 
       Timeline  
Caribou Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Caribou Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Caribou Biosciences is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.
Cognition Therapeutics 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Cognition Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Cognition Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Caribou Biosciences and Cognition Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Caribou Biosciences and Cognition Therapeutics

The main advantage of trading using opposite Caribou Biosciences and Cognition Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Caribou Biosciences position performs unexpectedly, Cognition Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cognition Therapeutics will offset losses from the drop in Cognition Therapeutics' long position.
The idea behind Caribou Biosciences and Cognition Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets